Welcome to our dedicated page for Talphera SEC filings (Ticker: tlph), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Talphera’s drug-development disclosures can feel like navigating a medical journal. Each 10-K details nafamostat pharmacology, clinical-trial costs, and cash runway forecasts—vital yet deeply technical. Add 8-K notices on FDA Breakthrough Device designations and you have a stack of documents few investors can finish. That’s why Stock Titan pairs Talphera’s complete SEC feed with AI-powered summaries that translate chemistry jargon into actionable data.
Use our platform to answer the questions people actually ask: “Where is Talphera’s quarterly earnings report 10-Q filing?” or “How do I track Talphera insider trading Form 4 transactions?” We surface every form the moment it hits EDGAR—10-K annual reports, 10-Q quarterlies, 8-K material events, S-1 offerings, and definitive proxy statements. Want specifics? The 10-K section on R&D spend is linked to charts, Form 4 insider transactions real-time alerts flag when executives buy shares before NEPHRO study results, and proxy statement executive compensation tables are distilled into clear comparisons.
Here’s how it helps you work faster:
- AI-generated overviews that make Talphera SEC filings explained simply
- Real-time e-mail or SMS when a new Talphera 8-K material events explained filing appears
- Side-by-side earnings report filing analysis for sequential trial spending trends
- Clickable links to Talphera annual report 10-K simplified, plus understanding Talphera SEC documents with AI video guides
- Filters for Talphera executive stock transactions Form 4 and historical option grants
Whether you monitor dilution risk ahead of a secondary offering or compare quarter-over-quarter burn rates, Stock Titan supplies every disclosure—clarified, organized, and always current.
Talphera, Inc. completed an optional second and third closing of its previously disclosed private placement, generating approximately $1.6 million in aggregate gross proceeds, excluding any proceeds from future exercises of the pre-funded warrants issued at this closing.
The company reiterated existing registration rights, agreeing to file registration statements for the resale of common shares issued in the private placement and shares underlying pre-funded warrants within 15 days of the applicable closing, and to use reasonable best efforts to have them declared effective as promptly as practical, and in any event within 90 days in the event of a full SEC review.
Separately, Talphera was notified on October 20, 2025 that it regained compliance with Nasdaq’s minimum bid price requirement, after the closing bid price met or exceeded $1.00 for 10 consecutive business days ending October 17, 2025, following its earlier transfer to The Nasdaq Capital Market.
Talphera appointed Joseph Todisco as a Class III director and compensation committee member, serving until the 2026 annual meeting. In connection with his appointment, he received 6,397 restricted stock units and options to purchase 38,381 shares at an exercise price of $1.11, vesting in three equal annual installments beginning on October 14, 2025, subject to continued service. The company also intends to enter into a non‑employee director indemnification agreement with him.
The board seat was designated under a securities purchase agreement with CorMedix. While CorMedix and affiliates beneficially own at least 25% of the shares it purchased at the first closing, it may designate one Talphera director. The agreement grants CorMedix a 60‑day Right of First Negotiation following Talphera’s public announcement of achieving the primary endpoint and topline results in the NEPHRO CRRT study for Niyad, during which Talphera will not engage with other parties on a similar transaction. If no agreement is reached, for nine months from that announcement Talphera will not enter a similar deal on less favorable financial terms without CorMedix’s consent. The right ends upon a public termination of the study before the primary endpoint or on December 31, 2027.
Talphera, Inc. (TLPH) filed a Form 3 for director Joseph Todisco. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/14/2025. The form indicates it was filed by one reporting person and reflects Todisco’s role as a director.
Talphera, Inc. (TLPH) reported a director equity grant on a Form 4. On 10/15/2025, the director received 6,397 restricted stock units at $0 and a stock option for 38,381 shares with a $1.11 exercise price.
Both the RSUs and the option vest in three equal annual installments on October 14, 2026, October 14, 2027, and October 14, 2028, with continuous service required for the option. Following these transactions, the filing lists 6,397 shares of common stock and 38,381 options as directly owned.
Laurence W. Lytton and the Lytton-Kambara Foundation each report shared beneficial ownership of 3,636,364 shares of Talphera, Inc. common stock, representing 8.0% of the class. The filing states the percentage was calculated using 20,522,655 shares outstanding as of August 7, 2025, and 25,036,360 shares issued in a private placement on September 10, 2025. Both reporting persons disclose no sole voting or dispositive power and shared voting and dispositive power over the reported shares. The certification affirms the shares were not acquired to change or influence control of the issuer.
Talphera, Inc. filed a Form D announcing a Rule 506(b) exempt offering of equity and related option securities. The company registered a total offering size of $28,969,997, of which $16,984,999 has been sold and $11,984,998 remains available. The notice lists 13 investors so far and indicates the issuer intends the offering to remain open for more than one year.
The filing shows a $0 minimum investment, no sales commissions or finders' fees reported, and no proceeds designated for executive officers, directors, or promoters. The Form D was signed by CFO Raffi Asadorian.
Talphera, Inc. filed a Current Report on Form 8-K disclosing a registration rights agreement related to a private placement dated September 7, 2025. Under the agreement the company agreed to file registration statements covering resale of the common stock issued in the private placement no later than 15 days following the applicable closing date and to use reasonable best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days following the applicable closing date if the SEC conducts a full review. The filing states the offering was made in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and the securities have not been registered. The form of the Registration Rights Agreement is filed as Exhibit 10.3, alongside the purchase agreement and warrant forms listed in Item 9.01.
FAQ
What is the current stock price of Talphera (tlph)?
What is the market cap of Talphera (tlph)?
